Omar Abudayyeh and Jonathan Gootenberg are exploring how peptides influence cells at scale. By linking peptide libraries directly to cells and tracking changes in growth or gene expression, they’re revealing how biology programs itself @jgooten@omarabudayyeh
Parag Mallick is building tools to measure proteins one molecule at a time. By moving beyond bulk averages, single-molecule proteomics can reveal biology we’ve never been able to see before. @paragmallick
Don Ingber explains how organ on a chip systems work because they include physical forces like flow and stretch. In lung chips, mimicking breathing is what makes real biology emerge. Mechanics matter as much as genes. @DonIngber
Breakthrough science at the Wyss Institute is powered by people. Don Ingber highlights how leaders across genome engineering, synthetic biology, diagnostics, and drug delivery come together to turn ideas into real-world impact. @DonIngber
For decades, scientists missed key structures inside cells because they were invisible to early imaging. Don Ingber connected those filaments to tensegrity, showing that physical forces shape cells just as much as genes and chemistry. @DonIngber
Don Ingber traced his path into biology back to something unexpected: 3D design. Learning that molecular shape drives function, from DNA to viruses, changed how he saw cells and ultimately how he approached biology itself. @DonIngber
Don Ingber explains why organs can’t be modeled with cells alone. On organ chips, flow, stretching, and motion like breathing or peristalsis are essential to recreate real organ function. Biology runs on physical forces, not just genes. @DonIngber
Don Ingber warned that the biggest risk to American science isn’t funding, it’s people. Fewer Americans are entering research, visa barriers are rising, and young scientists are the ones who actually make breakthroughs happen. @DonIngber
Don Ingber explained how medicine often hinges on tipping points, not linear fixes. In sepsis, a small change in pathogen load can decide recovery or collapse. His team explored removing pathogens directly to push biology back across that threshold. @DonIngber
Don Ingber explains why tensegrity matters. The body is shaped and stabilized by tension, not rigid parts, and those mechanical forces directly influence biology, from how cells behave to how we treat disease. @DonIngber
Don Ingber shared how organ on chip technology is advancing personalized cancer care. By testing patient derived tumor cells under realistic drug flow, the chips accurately predicted which chemotherapy patients with esophageal cancer would respond to next. @DonIngber
Don Ingber explains why biology isn’t just about genes. Mechanical forces shape how cells behave, an insight that led to organs on chips, mechanobiology, and new ways to replace animal testing and rethink human health. @DonIngber
Shelby Newsad shared why the future of biotech depends on integration, not rogue treatments. Enhancements only scale if they’re embedded in healthcare systems, approved, and covered, not flown to overseas clinics. @shelbynewsad
From rare disease communities to biohackers, Shelby Newsad described a future where people take far more control over their health, as tools like LLMs make biology more accessible and personalized medicine becomes increasingly self directed. @shelbynewsad
Shelby Newsad pointed out how expensive lab tools like bioanalyzers quietly limit biology. Better hardware paired with software that captures scientific know how could unlock faster, more reproducible experiments and real progress in biotech. @shelbynewsad
Shelby Newsad, Partner at Compound VC, explains why rare diseases are the smartest starting point for DNA repair and longevity. Clear mechanisms allow faster proof, earlier validation, and a path from rare conditions to broader impact in aging and cancer.
In our latest conversation, Shelby Newsad, Partner at Compound VC, shares how curiosity across biology led her into biotech investing. For her, commercialization is where scientific ideas are tested to see if they are ready for the real world. @shelbynewsad
Not every scientific idea is meant to scale. Shelby Newsad’s path into biotech VC came from wanting to see which ones actually do, where biology meets markets and ideas are tested in the real world. @shelbynewsad
In our discussion, Shelby Newsad shared how biology may mirror computing, shifting from scarce, specialized tools to everyday infrastructure as AI and closed loop experiments mature. @shelbynewsad
Shelby Newsad, Partner at Compound VC, on the future: people will prompt engineer their own drugs within 10 to 15 years. The biggest shift in biotech isn't tech, it's who holds agency over health. @shelbynewsad
In my conversation with Shelby Newsad, she highlighted how global access to treatments is reshaping biotech leadership and why the future of human enhancement will depend on building companies that can scale and stay profitable. @shelbynewsad